Leerink Analyst Says Prescriptions for Amarin's Vascepa 'Tracking Well'

Leerink Swann's Joseph Schwartz issued a note earlier Monday suggesting prescriptions for Amarin's (NASDAQ: AMRN ) Vascepa are "tracking well." The analyst said recent IMS data showed Vascepa prescriptions through the eleventh week are at 1,504 per week. Refills are at 13 percent. Schwartz called this level of prescriptions to